Johanna Vikkula
Overview
Explore the profile of Johanna Vikkula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mattila K, Tiainen L, Vikkula J, Kreutzman A, Engstrom-Risku M, Kysenius K, et al.
Future Oncol
. 2024 Sep;
20(40):3491-3505.
PMID: 39345100
First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT). Retrospective...
2.
Hannuksela N, Partanen A, Anttalainen A, Ukkola-Vuoti L, Toppila I, Vikkula J, et al.
Blood Cancer J
. 2024 Aug;
14(1):139.
PMID: 39164236
No abstract available.
3.
Vikkula J, Uusi-Rauva K, Ranki T, Toppila I, Aalto-Setala M, Pousar K, et al.
Future Oncol
. 2023 Oct;
19(30):2029-2043.
PMID: 37828901
The rapid development of multiple myeloma (MM) management underscores the value of real-world data. In our study we examined 509 adult MM patients treated with immunochemotherapy (ICT) with/without stem cell...
4.
Kiiski V, Ukkola-Vuoti L, Vikkula J, Ranta M, Lassenius M, Kopra J
Acta Derm Venereol
. 2023 Mar;
103:adv00882.
PMID: 36883876
The majority of registry studies on atopic dermatitis include only patients and diagnoses from specialized healthcare. The aim of this retrospective, real-world cohort study was to evaluate the effect of...
5.
Huuhtanen J, Kasanen H, Peltola K, Lonnberg T, Glumoff V, Bruck O, et al.
J Clin Invest
. 2023 Jan;
133(6).
PMID: 36719749
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on...
6.
Sumelahti M, Sumanen M, Sumanen M, Tuominen S, Vikkula J, Honkala S, et al.
J Headache Pain
. 2020 Sep;
21(1):118.
PMID: 32993489
Background: A global My Migraine Voice survey was conducted in 31 countries among 11,266 adults who suffered from ≥4 monthly migraine days (MMD). The aim of this retrospective observational survey-based...